SeLux Diagnostics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SeLux Diagnostics, Inc. - overview
Established
2014
Location
-, MA, US
Primary Industry
Biotechnology
About
Founded in 2014 and based in Massachusetts, US, SeLux Diagnostics, Inc. develops a phenotyping platform for treating infectious diseases. As of 2024, the company is headed by its CEO Steve Lufkin. The company was co-founded by Eric Stern and Aleksandar Vacic.
In April 2024, the firm raised USD 48 million in venture funding led by returning investor RA Capital Management, with participation from other returning investors Northpond Ventures, Sands Capital Ventures, and Schooner Capital. Selux Diagnostics' product is the Selux NGP System which provides automated aminotransferase (AST) results and personalized therapy results for all patients suffering from infectious disease. Diagnostic results are delivered by this technique in the same shift as positive blood cultures. Comprehensive testing for all sample types and antibiotics is offered by the Selux NGP System.
The company plans to use the April 2024 funding to support its commercialization across the United States.
Current Investors
RA Capital Management, Schooner Capital, Sands Capital Alternatives
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic Equipment
Website
www.seluxdx.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.